Shares of ResMed Inc. RMD slid 3.83% to $205.17 Friday, on what proved to be an all-around dismal trading session for the ...

We recently published a list of Jim Cramer is Discussing These 10 Stocks Ahead of Q1 Earnings Season. In this article, we are ...

Home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea.  | ...

BofA lowered the firm’s price target on ResMed (RMD) to $280 from $290 and keeps a Buy rating on the shares. The firm updated its model for ...

We came across a bullish thesis on ResMed Inc. (RMD) on Substack by LongTermValue Research. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc. (RMD)’s share was trading at $223 ...

StockNews.com downgraded shares of ResMed (NYSE:RMD – Free Report) from a buy rating to a hold rating in a research report report published on Wednesday morning. A number of other equities research ...

NightOwl is now widely available across the United States. Individuals interested in NightOwl should speak with their healthcare provider for more information. To learn more, visit: https://www.resmed ...

NightOwl, an FDA-cleared home sleep apnea test (HSAT) offers a simplified, accurate, efficient way to diagnose obstructive sleep apnea (OSA). It adds another offering to Resmed’s portfolio, which is ...

Leading health technology, Resmed, has announced its home sleep apnea test, NightOwl, is now available across the United ...

People have complained about Apple Vision Pro's weight, so ResMed built the Kontor Head Strap that helps by adding ...

ResMed Inc. closed 18.89% short of its 52-week high of $263.05, which the company reached on January 30th.

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its ...